CAV2

Across TCGA pan-cancer cohorts, CAV2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CAV2 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAV2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAV2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where CAV2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.247	0.571	.003	42	view →
LSCC	OS	Quartile	All	0.637	0.924	.006	20	view →
GBM	OS	Quartile	All	0.775	0.996	.001	15	view →
COAD	DFS	Median	III,IV	0.838	1.000	.037	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
HNSC	DFS	Tertile	All	1.000	0.930	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CAV2–PDAC (DFS)

Open the PDAC breakdown →